Results 21 to 30 of about 8,815 (184)

Comparison of Primary Patency Rate between Drug- Coated Balloon and Plain Balloon Angioplasty in Hemodialysis Access

Siriraj Medical Journal, 2022
Objective: Hemodialysis adequacy in end-stage renal disease patients plays a crucial role in their quality of life. Repeated stenosis at the anastomotic site of arteriovenous fistula and synthetic arteriovenous graft are a major cause of access failure ...
Trakarn Chaivanit, Pechngam Chaivanit, Pakpume Bumrungrachapukdee, Pongtrip Unprasert, Krittanont Wattanavaekin, Thoetphum Benyakorn   +5 more
doaj   +1 more source

Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial

Trials, 2021
Background Endovascular revascularization has established as the first-line therapy of femoropopliteal artery disease. Paclitaxel-coated balloon angioplasty proved to be superior to plain old balloon angioplasty (POBA) regarding prevention of restenosis ...
Ulf Teichgräber, Maja Ingwersen, Stephanie Platzer, Thomas Lehmann, Thomas Zeller, René Aschenbach, Dierk Scheinert   +6 more
doaj   +1 more source

Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends

Bioactive Materials, 2023
Purpose: This review aims to explore the history, research hotspots, and emerging trends of drug-eluting stents(DES)in the last two decades from the perspective of structural and temporal dynamics.
Lili Tan, Xiangxiu Wang, Kungshan Yuan, Tieying Yin, Ruolin Du, Li Shen, Zhirong Zhu, Suhua Yu, Haijun Zhang, Guixue Wang   +9 more
doaj   +1 more source

Drug-coated balloons: Technical and clinical progress [PDF]

Vascular Medicine, 2020
The advancement of drug-coated balloons (DCB) presents an alternative nonstent method in the percutaneous treatment of atherosclerotic lesions. While the current generation of drug-eluting stents (DES) are the device of choice, especially in coronary artery disease (CAD), DCB has potential applications in the treatment of de novo lesions, in-stent ...
Huiying Ang, Tobias R Koppara, Salvatore Cassese, Jaryl Ng, Michael Joner, Nicolas Foin   +5 more
openaire   +2 more sources

Debate. Drug-coated balloons for de novo coronary artery lesions. Evidence available and potential superiority in some settings

REC: Interventional Cardiology (English Ed.), 2023
QUESTION: What is the evidence available on the use of drug-coated balloons (DCB) in the de novo lesion setting? ANSWER: The use of DCB to treat de novo lesions is the most compelling argument regarding this technology, an area that has advanced ...
Bernardo Cortese
doaj   +1 more source

Sustained drug retention after paclitaxel-coated balloon angioplasty for superficial femoral artery disease: Follow-up intravascular imaging

SAGE Open Medical Case Reports, 2020
A 63 year-old woman with claudication underwent endovascular therapy for diffuse stenosis of the right superficial femoral artery in our hospital. We performed paclitaxel-coated balloon angioplasty using the IN.PACT™ Admiral™ and achieved acceptable ...
Norihiro Kobayashi, Keisuke Hirano, Masahiro Yamawaki, Motoharu Araki, Tsuyoshi Sakai, Yasunari Sakamoto, Shinsuke Mori, Masakazu Tsutsumi, Masahiro Nauchi, Naohiko Sahara, Yohsuke Honda, Kenji Makino, Shigemitsu Shirai, Masafumi Mizusawa, Yuta Sugizaki, Takahide Nakano, Tomoya Fukagawa, Toshihiko Kishida, Yuki Kozai, Yusuke Setonaga, Shutaro Goda, Yoshiaki Ito   +21 more
doaj   +1 more source

Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction

Journal of Cardiothoracic Surgery, 2021
background Drug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis. The purpose of this article is to observe the safety and effectiveness of drug-
Little teacher is good, Damien Yellow, Asaka King, Jin Chun Zhang, Li Hongqiang Liu, Yingmin road   +5 more
doaj   +1 more source

The Development of an ex vivo Flow System to Assess Acute Arterial Drug Retention of Cardiovascular Intravascular Devices

Frontiers in Medical Technology, 2021
Purpose: The goal of this study was to develop an ex vivo system capable of rapidly evaluating arterial drug levels in living, isolated porcine carotid arteries.Methods: A vascular bioreactor system was developed that housed a native porcine carotid ...
Kathryn Cooper, Claire V. Cawthon, Emily Goel, Marzieh Atigh, Uwe Christians, Saami K. Yazdani   +5 more
doaj   +1 more source

RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease

Hepatology, EarlyView., 2022
RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease. Abstract Background and Aims Receptor‐interacting protein kinase 3 (RIPK3) mediates NAFLD progression, but its metabolic function is unclear. Here, we aimed to investigate the role of RIPK3 in modulating mitochondria function, coupled with lipid droplet (LD)
Marta B. Afonso, Tawhidul Islam, Julie Magusto, Ricardo Amorim, Véronique Lenoir, Rui F. Simões, José Teixeira, Liana C. Silva, Dominique Wendum, Isabelle Jéru, Corinne Vigouroux, Rui E. Castro, Paulo J. Oliveira, Carina Prip‐Buus, Vlad Ratziu, Jérémie Gautheron, Cecília M. P. Rodrigues   +16 more
wiley   +1 more source

Drug-Coated Balloons for In-Stent Restenosis

Journal of the American College of Cardiology, 2020
The DAEDALUS (Difference in Antirestenotic Effectiveness of Drug-Eluting Stent and Drug-Coated Balloon Angioplasty for the Occurrence of Coronary In-Stent Restenosis) meta-analysis aggregates 10 randomized controlled trials comparing drug-coated balloons (DCB) with drug-eluting stents (DES ...
Dean J, Kereiakes, David E, Kandzari, James P, Zidar   +2 more
openaire   +2 more sources